aluates Reports

$ 0.0

Automative

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Research Report 2026

Published Date: 2026-02-04

Report Code: QYRE-Auto-5U12923

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Research Report 2023

BUY CHAPTERS

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Research Report 2026

Code: QYRE-Auto-5U12923

Report

2026-02-04

Pages:120

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Dako (Agilent Technologies)

Merck

Abbott

Genesys Biolabs (20/20GeneSystems)

Affymetrix Inc

Agendia

ALMAC

Arrayit

Biocartic

BG Medicine

KEGG EXPRESSION Database

Thermo Fisher

BGI

Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size

The global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market was valued at US$ 24490 million in 2025 and is anticipated to reach US$ 33850 million by 2032, at a CAGR of 4.8% from 2026 to 2032.

Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market

A biomarker is, according to the US National Institutes of Health, “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”

Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.

Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.

We can discriminate four main types of molecular biomarkers:

• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.

• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.

• Proteomic biomarkers: Base on the analysis of the protein profiles.

• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).

Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.

The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.

This report delivers a comprehensive overview of the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Commercializing Biomarkers in Therapeutic and Diagnostic Applications. The Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Commercializing Biomarkers in Therapeutic and Diagnostic Applications manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Report

Report Metric	Details
Report Name	Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market
Accounted market size in 2025	US$ 24490 million
Forecasted market size in 2032	US$ 33850 million
CAGR	4.8%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Consumables Services Software
Segment by Application	Oncology Cardiology Neurology Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia, ALMAC, Arrayit, Biocartic, BG Medicine, KEGG EXPRESSION Database, Thermo Fisher, BGI
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market growing?

Ans: The Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market witnessing a CAGR of 4.8% during the forecast period 2026-2032.

What is the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market size in 2032?

Ans: The Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market size in 2032 will be US$ 33850 million.

What is the market share of major companies in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market?

Ans: The top 3 players occupy about 10% shares of the global market.

What is the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market share by type?

Ans: Consumables is the main type, with a share about 60%.

Who are the main players in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market report?

Ans: The main players in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market are Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia, ALMAC, Arrayit, Biocartic, BG Medicine, KEGG EXPRESSION Database, Thermo Fisher, BGI

What are the Application segmentation covered in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market report?

Ans: The Applications covered in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market report are Oncology, Cardiology, Neurology, Other

What are the Type segmentation covered in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market report?

Ans: The Types covered in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market report are Consumables, Services, Software

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Consumables

1.2.3 Services

1.2.4 Software

1.3 Market by Application

1.3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Oncology

1.3.3 Cardiology

1.3.4 Neurology

1.3.5 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Perspective (2021–2032)

2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Growth Trends by Region

2.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Region (2021–2026)

2.2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Region (2027–2032)

2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Dynamics

2.3.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Trends

2.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers

2.3.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges

2.3.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue

3.1.1 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue (2021–2026)

3.1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Players (2021–2026)

3.2 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue

3.4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio

3.4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2025

3.5 Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Head Offices and Areas Served

3.6 Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Products and Applications

3.7 Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Type

4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Type (2021–2026)

4.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Type (2027–2032)

5 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Application

5.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Application (2021–2026)

5.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2021–2032)

6.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2021–2026)

6.4 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2021–2032)

7.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2021–2026)

7.4 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2021–2032)

8.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2021–2026)

8.4 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2021–2032)

9.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2021–2026)

9.4 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2021–2032)

10.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2021–2026)

10.4 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.1.4 Roche Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.1.5 Roche Recent Development

11.2 Dako (Agilent Technologies)

11.2.1 Dako (Agilent Technologies) Company Details

11.2.2 Dako (Agilent Technologies) Business Overview

11.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.2.4 Dako (Agilent Technologies) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.2.5 Dako (Agilent Technologies) Recent Development

11.3 Merck

11.3.1 Merck Company Details

11.3.2 Merck Business Overview

11.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.3.4 Merck Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.3.5 Merck Recent Development

11.4 BD

11.4.1 BD Company Details

11.4.2 BD Business Overview

11.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.4.4 BD Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.4.5 BD Recent Development

11.5 Abbott

11.5.1 Abbott Company Details

11.5.2 Abbott Business Overview

11.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.5.4 Abbott Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.5.5 Abbott Recent Development

11.6 Genesys Biolabs (20/20GeneSystems)

11.6.1 Genesys Biolabs (20/20GeneSystems) Company Details

11.6.2 Genesys Biolabs (20/20GeneSystems) Business Overview

11.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.6.4 Genesys Biolabs (20/20GeneSystems) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.6.5 Genesys Biolabs (20/20GeneSystems) Recent Development

11.7 Affymetrix

11.7.1 Affymetrix Company Details

11.7.2 Affymetrix Business Overview

11.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.7.4 Affymetrix Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.7.5 Affymetrix Recent Development

11.8 Agendia

11.8.1 Agendia Company Details

11.8.2 Agendia Business Overview

11.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.8.4 Agendia Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.8.5 Agendia Recent Development

11.9 ALMAC

11.9.1 ALMAC Company Details

11.9.2 ALMAC Business Overview

11.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.9.4 ALMAC Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.9.5 ALMAC Recent Development

11.10 Arrayit

11.10.1 Arrayit Company Details

11.10.2 Arrayit Business Overview

11.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.10.4 Arrayit Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.10.5 Arrayit Recent Development

11.11 Biocartic

11.11.1 Biocartic Company Details

11.11.2 Biocartic Business Overview

11.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.11.4 Biocartic Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.11.5 Biocartic Recent Development

11.12 BG Medicine

11.12.1 BG Medicine Company Details

11.12.2 BG Medicine Business Overview

11.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.12.4 BG Medicine Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.12.5 BG Medicine Recent Development

11.13 KEGG EXPRESSION Database

11.13.1 KEGG EXPRESSION Database Company Details

11.13.2 KEGG EXPRESSION Database Business Overview

11.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.13.4 KEGG EXPRESSION Database Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.13.5 KEGG EXPRESSION Database Recent Development

11.14 Thermo Fisher

11.14.1 Thermo Fisher Company Details

11.14.2 Thermo Fisher Business Overview

11.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.14.4 Thermo Fisher Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.14.5 Thermo Fisher Recent Development

11.15 BGI

11.15.1 BGI Company Details

11.15.2 BGI Business Overview

11.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction

11.15.4 BGI Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

11.15.5 BGI Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Roche

Dako (Agilent Technologies)

Merck

Abbott

Genesys Biolabs (20/20GeneSystems)

Affymetrix Inc

Agendia

ALMAC

Arrayit

Biocartic

BG Medicine

KEGG EXPRESSION Database

Thermo Fisher

BGI

List of Tables

Table 1. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Consumables

Table 3. Key Players of Services

Table 4. Key Players of Software

Table 5. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 6. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (US$ Million), 2021–2026

Table 8. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Region (2021–2026)

Table 9. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Region (US$ Million), 2027–2032

Table 10. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Region (2027–2032)

Table 11. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Trends

Table 12. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers

Table 13. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges

Table 14. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints

Table 15. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Players (US$ Million), 2021–2026

Table 16. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Players (2021–2026)

Table 17. Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Tier (Tier 1, Tier 2, and Tier 3), based on Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2025

Table 18. Ranking of Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies by Revenue (US$ Million) in 2025

Table 19. Global 5 Largest Players Market Share by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (CR5 and HHI), 2021–2026

Table 20. Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Headquarters and Area Served

Table 21. Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Products and Applications

Table 22. Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, Date of General Availability (GA)

Table 23. Mergers and Acquisitions, Expansion Plans

Table 24. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (US$ Million), 2021–2026

Table 25. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Type (2021–2026)

Table 26. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Type (US$ Million), 2027–2032

Table 27. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Type (2027–2032)

Table 28. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (US$ Million), 2021–2026

Table 29. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Application (2021–2026)

Table 30. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Application (US$ Million), 2027–2032

Table 31. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Application (2027–2032)

Table 32. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 33. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (US$ Million), 2021–2026

Table 34. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (US$ Million), 2027–2032

Table 35. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 36. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (US$ Million), 2021–2026

Table 37. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (US$ Million), 2027–2032

Table 38. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 39. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (US$ Million), 2021–2026

Table 40. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (US$ Million), 2027–2032

Table 41. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 42. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (US$ Million), 2021–2026

Table 43. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (US$ Million), 2027–2032

Table 44. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 45. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (US$ Million), 2021–2026

Table 46. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (US$ Million), 2027–2032

Table 47. Roche Company Details

Table 48. Roche Business Overview

Table 49. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 50. Roche Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 51. Roche Recent Development

Table 52. Dako (Agilent Technologies) Company Details

Table 53. Dako (Agilent Technologies) Business Overview

Table 54. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 55. Dako (Agilent Technologies) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 56. Dako (Agilent Technologies) Recent Development

Table 57. Merck Company Details

Table 58. Merck Business Overview

Table 59. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 60. Merck Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 61. Merck Recent Development

Table 62. BD Company Details

Table 63. BD Business Overview

Table 64. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 65. BD Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 66. BD Recent Development

Table 67. Abbott Company Details

Table 68. Abbott Business Overview

Table 69. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 70. Abbott Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 71. Abbott Recent Development

Table 72. Genesys Biolabs (20/20GeneSystems) Company Details

Table 73. Genesys Biolabs (20/20GeneSystems) Business Overview

Table 74. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 75. Genesys Biolabs (20/20GeneSystems) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 76. Genesys Biolabs (20/20GeneSystems) Recent Development

Table 77. Affymetrix Company Details

Table 78. Affymetrix Business Overview

Table 79. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 80. Affymetrix Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 81. Affymetrix Recent Development

Table 82. Agendia Company Details

Table 83. Agendia Business Overview

Table 84. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 85. Agendia Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 86. Agendia Recent Development

Table 87. ALMAC Company Details

Table 88. ALMAC Business Overview

Table 89. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 90. ALMAC Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 91. ALMAC Recent Development

Table 92. Arrayit Company Details

Table 93. Arrayit Business Overview

Table 94. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 95. Arrayit Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 96. Arrayit Recent Development

Table 97. Biocartic Company Details

Table 98. Biocartic Business Overview

Table 99. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 100. Biocartic Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 101. Biocartic Recent Development

Table 102. BG Medicine Company Details

Table 103. BG Medicine Business Overview

Table 104. BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 105. BG Medicine Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 106. BG Medicine Recent Development

Table 107. KEGG EXPRESSION Database Company Details

Table 108. KEGG EXPRESSION Database Business Overview

Table 109. KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 110. KEGG EXPRESSION Database Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 111. KEGG EXPRESSION Database Recent Development

Table 112. Thermo Fisher Company Details

Table 113. Thermo Fisher Business Overview

Table 114. Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 115. Thermo Fisher Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 116. Thermo Fisher Recent Development

Table 117. BGI Company Details

Table 118. BGI Business Overview

Table 119. BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product

Table 120. BGI Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (US$ Million), 2021–2026

Table 121. BGI Recent Development

Table 122. Research Programs/Design for This Report

Table 123. Key Data Information from Secondary Sources

Table 124. Key Data Information from Primary Sources

Table 125. Authors List of This Report

List of Figures

Figure 1. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture

Figure 2. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type: 2025 vs 2032

Figure 4. Consumables Features

Figure 5. Services Features

Figure 6. Software Features

Figure 7. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (US$ Million), 2021–2032

Figure 8. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application: 2025 vs 2032

Figure 9. Oncology Case Studies

Figure 10. Cardiology Case Studies

Figure 11. Neurology Case Studies

Figure 12. Other Case Studies

Figure 13. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Report Years Considered

Figure 14. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 15. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 16. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Region: 2025 vs 2032

Figure 17. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Players in 2025

Figure 18. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 19. The Top 10 and 5 Players Market Share by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2025

Figure 20. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 21. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Country (2021–2032)

Figure 22. United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Canada Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Country (2021–2032)

Figure 26. Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. U.K. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Ireland Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Region (2021–2032)

Figure 34. China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Australia & New Zealand Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Country (2021–2032)

Figure 42. Mexico Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Brazil Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Country (2021–2032)

Figure 46. Israel Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Saudi Arabia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. UAE Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Roche Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 50. Dako (Agilent Technologies) Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 51. Merck Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 52. BD Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 53. Abbott Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 54. Genesys Biolabs (20/20GeneSystems) Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 55. Affymetrix Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 56. Agendia Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 57. ALMAC Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 58. Arrayit Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 59. Biocartic Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 60. BG Medicine Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 61. KEGG EXPRESSION Database Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 62. Thermo Fisher Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 63. BGI Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021–2026)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed